L. Discordance-entre and L. Fish, 95 3.1. Comment expliquer ces deux cas discordants ?, p.96

J. Ferlay, D. Parkin, and E. Steliarova-foucher, Estimates of cancer incidence and mortality in Europe in 2008, European Journal of Cancer, vol.46, issue.4, pp.765-81, 2010.
DOI : 10.1016/j.ejca.2009.12.014

A. Belot, P. Grosclaude, N. Bossard, E. Jougla, E. Benhamou et al., Cancer incidence and mortality in France over the period 1980???2005, Revue d'??pid??miologie et de Sant?? Publique, vol.56, issue.3, pp.159-75, 2008.
DOI : 10.1016/j.respe.2008.03.117

URL : https://hal.archives-ouvertes.fr/hal-00538673

A. Davidoff, M. Tang, B. Seal, and M. Edelman, Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.28, issue.13, pp.2191-2198, 2010.
DOI : 10.1200/JCO.2009.25.4052

F. Blanchon, M. Grivaux, T. Collon, M. Zureik, H. Barbieux et al., Epidemiologic of primary bronchial carcinoma management in the general French hospital centers], Rev Mal Respir, vol.19, pp.727-761, 2002.

M. Thun, C. Lally, J. Flannery, E. Calle, W. Flanders et al., Cigarette Smoking and Changes in the Histopathology of Lung Cancer, JNCI Journal of the National Cancer Institute, vol.89, issue.21, pp.1580-1586, 1997.
DOI : 10.1093/jnci/89.21.1580

N. Wirth, A. Bohadana, A. Spinosa, and Y. Martinet, Les pathologies respiratoires li??es au tabagisme passif, Revue des Maladies Respiratoires, vol.26, issue.6, pp.667-78, 2009.
DOI : 10.1016/S0761-8425(09)74696-0

A. Hackshaw, Lung cancer and passive smoking, Statistical Methods in Medical Research, vol.99, issue.2, pp.119-155, 1998.
DOI : 10.1177/096228029800700203

P. Boffetta, P. Autier, M. Boniol, P. Boyle, C. Hill et al., An Estimate of Cancers Attributable to Occupational Exposures in France, Journal of Occupational and Environmental Medicine, vol.52, issue.4, pp.399-406, 2010.
DOI : 10.1097/JOM.0b013e3181d5e355

URL : https://hal.archives-ouvertes.fr/hal-01260430

R. Lemen, J. Dement, and J. Wagoner, Epidemiology of asbestos-related diseases, Environmental Health Perspectives, vol.34, issue.11, pp.1-11, 1980.
DOI : 10.1289/ehp.80341

E. Quoix and E. Lemarie, ??pid??miologie du cancer bronchique primitif??: aspects classiques et nouveaut??s, Revue des Maladies Respiratoires, vol.28, issue.8, pp.1048-58, 2011.
DOI : 10.1016/j.rmr.2010.12.015

J. Berthiller, K. Straif, M. Boniol, N. Voirin, V. Benhaim-luzon et al., Cannabis Smoking and Risk of Lung Cancer in Men: A Pooled Analysis of Three Studies in Maghreb, Journal of Thoracic Oncology, vol.3, issue.12, pp.1398-403, 2008.
DOI : 10.1097/JTO.0b013e31818ddcde

URL : https://hal.archives-ouvertes.fr/hal-00428254

S. Aldington, M. Harwood, B. Cox, M. Weatherall, L. Beckert et al., Cannabis use and cancer of the head and neck: Case-control study, Otolaryngology-Head and Neck Surgery, vol.74, issue.3, pp.374-80, 2008.
DOI : 10.1016/j.otohns.2007.12.002

W. Travis, E. Brambilla, M. Noguchi, A. Nicholson, K. Geisinger et al., International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary, Proceedings of the American Thoracic Society, vol.8, issue.5, pp.381-386, 2011.
DOI : 10.1513/pats.201107-042ST

T. Nagano, G. Ishii, K. Nagai, T. Ito, A. Kawase et al., Structural and biological properties of a papillary component generating a micropapillary component in lung adenocarcinoma, Lung Cancer, vol.67, issue.3, pp.282-291, 2010.
DOI : 10.1016/j.lungcan.2009.04.014

S. Silver and F. Askin, True Papillary Carcinoma of the Lung, The American Journal of Surgical Pathology, vol.21, issue.1, pp.43-51, 1997.
DOI : 10.1097/00000478-199701000-00005

W. Travis, E. Brambilla, M. Noguchi, A. Nicholson, K. Geisinger et al., International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-85, 2011.
DOI : 10.1097/JTO.0b013e318206a221

URL : https://hal.archives-ouvertes.fr/inserm-00561753

K. Finberg, L. Sequist, V. Joshi, A. Muzikansky, J. Miller et al., Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features, The Journal of Molecular Diagnostics, vol.9, issue.3, pp.320-326, 2007.
DOI : 10.2353/jmoldx.2007.060182

Y. Sakuma, S. Matsukuma, M. Yoshihara, Y. Nakamura, K. Noda et al., Gene-Mutation Analyses for Japanese Lung Adenocarcinomas, American Journal of Clinical Pathology, vol.128, issue.1, pp.100-108, 2007.
DOI : 10.1309/WVXFGAFLAUX48DU6

M. Beasley, Immunohistochemistry of pulmonary and pleural neoplasia, Arch Pathol Lab Med, vol.132, pp.1062-72, 2008.

D. Lazzaro, M. Price, F. De, and L. Di, The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain, Development, vol.113, issue.22, pp.1093-104, 1991.

R. Bohinski, L. Di, and J. Whitsett, The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis., Molecular and Cellular Biology, vol.14, issue.9, pp.5671-81, 1994.
DOI : 10.1128/MCB.14.9.5671

A. Khoor, J. Whitsett, M. Stahlman, S. Olson, and P. Cagle, Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma, Human Pathology, vol.30, issue.6, pp.695-700, 1999.
DOI : 10.1016/S0046-8177(99)90096-5

W. Pao and N. Girard, New driver mutations in non-small-cell lung cancer, The Lancet Oncology, vol.12, issue.2, pp.175-80, 2011.
DOI : 10.1016/S1470-2045(10)70087-5

L. Thiberville, J. Bourguignon, J. Metayer, F. Bost, M. Diarra-mehrpour et al., Frequency and prognostic evaluation of 3p21-22 allelic losses in non-small-cell lung cancer, International Journal of Cancer, vol.215, issue.6
DOI : 10.1002/ijc.2910640604

S. Lantuejoul, D. Salameire, C. Salon, and E. Brambilla, Pulmonary preneoplasia - sequential molecular carcinogenetic events, Histopathology, vol.29, issue.1, pp.43-54, 2009.
DOI : 10.1111/j.1365-2559.2008.03182.x

URL : https://hal.archives-ouvertes.fr/inserm-00360878

E. Brambilla and A. Gazdar, Pathogenesis of lung cancer signalling pathways: roadmap for therapies, European Respiratory Journal, vol.33, issue.6, pp.1485-97, 2009.
DOI : 10.1183/09031936.00014009

S. Aviel-ronen, F. Blackhall, F. Shepherd, and M. Tsao, K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review, Clinical Lung Cancer, vol.8, issue.1, pp.30-38, 2006.
DOI : 10.3816/CLC.2006.n.030

N. Choong, R. Salgia, and E. Vokes, Key Signaling Pathways and Targets in Lung Cancer Therapy, Clinical Lung Cancer, vol.8, issue.30 2, pp.52-60, 2007.
DOI : 10.3816/CLC.2007.s.002

H. West, R. Lilenbaum, D. Harpole, A. Wozniak, and L. Sequist, Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.4, issue.9, pp.1029-1039, 2009.
DOI : 10.1097/JTO.0b013e3181b27170

B. Solomon and R. Pearson, Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.4, issue.7, pp.787-91, 2009.
DOI : 10.1097/JTO.0b013e3181a74dba

T. Reungwetwattana, S. Weroha, and J. Molina, Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non-Small-Cell Lung Cancer (NSCLC) Clin Lung Cancer, 2011.

J. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland et al., MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, Science, vol.316, issue.5827, pp.1039-1082, 2007.
DOI : 10.1126/science.1141478

M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita et al., Identification of the transforming EML4???ALK fusion gene in non-small-cell lung cancer, Nature, vol.276, issue.7153, pp.561-567, 2007.
DOI : 10.1038/nature05945

A. Mogi and H. Kuwano, TP53 Mutations in Nonsmall Cell Lung Cancer, Journal of Biomedicine and Biotechnology, vol.9, issue.3, p.583929, 2011.
DOI : 10.1038/nrd2656

P. Andujar, J. Wang, A. Descatha, F. Galateau-salle, I. Abd-alsamad et al., p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos, Lung Cancer, vol.67, issue.1, pp.23-30, 2010.
DOI : 10.1016/j.lungcan.2009.03.018

URL : https://hal.archives-ouvertes.fr/inserm-00388198

C. Rudin, E. Avila-tang, C. Harris, J. Herman, F. Hirsch et al., Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications, Clinical Cancer Research, vol.15, issue.18, pp.5646-61, 2009.
DOI : 10.1158/1078-0432.CCR-09-0377

J. Subramanian and R. Govindan, Molecular genetics of lung cancer in people who have never smoked, The Lancet Oncology, vol.9, issue.7, pp.676-82, 2008.
DOI : 10.1016/S1470-2045(08)70174-8

K. Pulford, S. Morris, and F. Turturro, Anaplastic lymphoma kinase proteins in growth control and cancer, Journal of Cellular Physiology, vol.168, issue.3, pp.330-58, 2004.
DOI : 10.1002/jcp.10472

R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami, The anaplastic lymphoma kinase in the pathogenesis of cancer, Nature Reviews Cancer, vol.159, issue.1, pp.11-23, 2008.
DOI : 10.1002/ijc.21490

F. Kelleher and R. Mcdermott, The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene, European Journal of Cancer, vol.46, issue.13, pp.2357-68, 2010.
DOI : 10.1016/j.ejca.2010.04.006

A. Barreca, E. Lasorsa, L. Riera, R. Machiorlatti, R. Piva et al., Anaplastic lymphoma kinase in human cancer, Journal of Molecular Endocrinology, vol.47, issue.1, pp.11-23, 2011.
DOI : 10.1530/JME-11-0004

E. Grande, M. Bolos, and E. Arriola, Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment, Molecular Cancer Therapeutics, vol.10, issue.4, pp.569-79, 2011.
DOI : 10.1158/1535-7163.MCT-10-0615

Y. Mosse, A. Wood, and J. Maris, Inhibition of ALK Signaling for Cancer Therapy, Clinical Cancer Research, vol.15, issue.18, pp.5609-5623, 2009.
DOI : 10.1158/1078-0432.CCR-08-2762

M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita et al., Identification of the transforming EML4???ALK fusion gene in non-small-cell lung cancer, Nature, vol.276, issue.7153, pp.561-567, 2007.
DOI : 10.1038/nature05945

K. Shinmura, S. Kageyama, H. Tao, T. Bunai, M. Suzuki et al., EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas, Lung Cancer, vol.61, issue.2, pp.163-172, 2008.
DOI : 10.1016/j.lungcan.2007.12.013

D. Wong, E. Leung, S. Wong, V. Tin, A. Sihoe et al., variant in nonsmall cell lung cancer, Cancer, vol.363, issue.12, pp.2709-2727, 2011.
DOI : 10.1002/cncr.25843

K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu et al., Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer, Cell, vol.131, issue.6, pp.1190-203, 2007.
DOI : 10.1016/j.cell.2007.11.025

K. Takeuchi, Y. Choi, Y. Togashi, M. Soda, S. Hatano et al., KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer, Clinical Cancer Research, vol.15, issue.9, pp.3143-3152, 2009.
DOI : 10.1158/1078-0432.CCR-08-3248

A. Shaw and B. Solomon, Targeting Anaplastic Lymphoma Kinase in Lung Cancer, Clinical Cancer Research, vol.17, issue.8, pp.2081-2087, 2011.
DOI : 10.1158/1078-0432.CCR-10-1591

Y. Li, X. Ye, J. Liu, J. Zha, and P. L. , Evaluation of EML4-ALK Fusion Proteins in Non???Small Cell Lung Cancer Using Small Molecule Inhibitors, Neoplasia, vol.13, issue.1, pp.1-11, 2011.
DOI : 10.1593/neo.101120

E. Kwak, Y. Bang, D. Camidge, A. Shaw, B. Solomon et al., Anaplastic Lymphoma Kinase Inhibition in Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.363, issue.18, pp.1693-703, 2010.
DOI : 10.1056/NEJMoa1006448

P. Yang, K. Kulig, J. Boland, M. Erickson-johnson, A. Oliveira et al., Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.7, issue.1, pp.90-97, 2012.
DOI : 10.1097/JTO.0b013e31823c5c32

S. Wu, Y. Kuo, Y. Chang, J. Shih, Y. Chen et al., EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR, Journal of Thoracic Oncology, vol.7, issue.1, pp.98-104, 2012.
DOI : 10.1097/JTO.0b013e3182370e30

A. Shaw and B. Solomon, Targeting Anaplastic Lymphoma Kinase in Lung Cancer, Clinical Cancer Research, vol.17, issue.8, pp.2081-2087, 2011.
DOI : 10.1158/1078-0432.CCR-10-1591

D. Gerber and J. Minna, ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time, Cancer Cell, vol.18, issue.6, pp.548-51, 2010.
DOI : 10.1016/j.ccr.2010.11.033

A. Shaw, B. Yeap, B. Solomon, G. Riely, J. Gainor et al., Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis, The Lancet Oncology, vol.12, issue.11, pp.1004-1016, 2011.
DOI : 10.1016/S1470-2045(11)70232-7

D. Camidge, M. Theodoro, D. Maxson, M. Skokan, O. Brien et al., Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer, Cancer, 2012.

J. Paik, C. Choi, H. Kim, S. Jang, G. Choe et al., Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma, Lung Cancer, issue.61, 2011.

M. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro et al., EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues, The American Journal of Pathology, vol.174, issue.2, pp.661-70, 2009.
DOI : 10.2353/ajpath.2009.080755

J. Paik, C. Choi, H. Kim, S. Jang, G. Choe et al., Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma, Lung Cancer, issue.64, 2011.

S. Ou, Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond, Drug Design, Development and Therapy, vol.5, pp.471-85, 2011.
DOI : 10.2147/DDDT.S19045

A. Yoshida, K. Tsuta, H. Nakamura, T. Kohno, F. Takahashi et al., Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas, The American Journal of Surgical Pathology, vol.35, issue.8, pp.1226-1260, 2011.
DOI : 10.1097/PAS.0b013e3182233e06

T. Ohba, K. Sugio, T. Kometani, M. Yamaguchi, M. Hamatake et al., Signet ring cell adenocarcinoma of the lung with an EML4???ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: A case report, Lung Cancer, vol.73, issue.3, pp.375-383, 2011.
DOI : 10.1016/j.lungcan.2011.05.016

K. Inamura, K. Takeuchi, Y. Togashi, S. Hatano, H. Ninomiya et al., EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset, Modern Pathology, vol.8, issue.4, pp.508-523, 2009.
DOI : 10.1158/0008-5472.CAN-06-4774

A. Yoshida, K. Tsuta, S. Watanabe, I. Sekine, M. Fukayama et al., Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component, Lung Cancer, vol.72, issue.3, pp.309-324, 2011.
DOI : 10.1016/j.lungcan.2010.09.013

T. Sasaki, S. Rodig, L. Chirieac, and P. Janne, The biology and treatment of EML4-ALK non-small cell lung cancer, European Journal of Cancer, vol.46, issue.10, pp.1773-80, 2010.
DOI : 10.1016/j.ejca.2010.04.002

A. Mcleer-florin, D. Moro-sibilot, A. Melis, D. Salameire, C. Lefebvre et al., Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study, Journal of Thoracic Oncology, vol.7, issue.2, pp.348-54, 2012.
DOI : 10.1097/JTO.0b013e3182381535

J. Paik, C. Choi, H. Kim, S. Jang, G. Choe et al., Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma, Lung Cancer, issue.72, 2011.

J. Paik, G. Choe, H. Kim, J. Choe, H. Lee et al., Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization, Journal of Thoracic Oncology, vol.6, issue.3, pp.466-72, 2011.
DOI : 10.1097/JTO.0b013e31820b82e8

M. Mino-kenudson, L. Chirieac, K. Law, J. Hornick, N. Lindeman et al., A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry, Clinical Cancer Research, vol.16, issue.5, pp.1561-71, 2010.
DOI : 10.1158/1078-0432.CCR-09-2845

S. Ou, Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond, Drug Design, Development and Therapy, vol.5, issue.75, pp.471-85, 2011.
DOI : 10.2147/DDDT.S19045

P. Just, A. Cazes, A. Audebourg, A. Cessot, K. Pallier et al., Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALKrearrangement in lung cancer: A comprehensive study of Caucasian non-smokers, Lung Cancer, issue.76, 2011.

D. Camidge, M. Theodoro, D. Maxson, M. Skokan, O. Brien et al., Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer, Cancer, 2012.

J. Paik, G. Choe, H. Kim, J. Choe, H. Lee et al., Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization, Journal of Thoracic Oncology, vol.6, issue.3, pp.466-72, 2011.
DOI : 10.1097/JTO.0b013e31820b82e8

E. Yi, J. Boland, J. Maleszewski, A. Roden, A. Oliveira et al., Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH, Journal of Thoracic Oncology, vol.6, issue.3, pp.459-65, 2011.
DOI : 10.1097/JTO.0b013e318209edb9

J. Paik, G. Choe, H. Kim, J. Choe, H. Lee et al., Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization, Journal of Thoracic Oncology, vol.6, issue.3, pp.466-72, 2011.
DOI : 10.1097/JTO.0b013e31820b82e8

J. Bishop, J. Teruya-feldstein, W. Westra, G. Pelosi, W. Travis et al., (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma, Mod Pathol, vol.25, issue.81, pp.40405-40420, 2012.

K. Whithaus, J. Fukuoka, T. Prihoda, and J. Jagirdar, Evaluation of Napsin A, Cytokeratin 5/6, p63, and Thyroid Transcription Factor 1 in Adenocarcinoma Versus Squamous Cell Carcinoma of the Lung, Archives of Pathology & Laboratory Medicine, vol.136, issue.2, pp.155-62, 2012.
DOI : 10.5858/arpa.2011-0232-OA